Stay updated on Pembrolizumab for Cancer of Unknown Primary Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab for Cancer of Unknown Primary Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab for Cancer of Unknown Primary Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The web page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.
    Difference
    1%
    Check dated 2025-05-29T15:17:09.000Z thumbnail image
  2. Check
    10 days ago
    No Change Detected
  3. Check
    17 days ago
    No Change Detected
  4. Check
    31 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.
    Difference
    0.1%
    Check dated 2025-05-01T03:33:03.000Z thumbnail image
  5. Check
    45 days ago
    Change Detected
    Summary
    The webpage has been updated to include the study's collaborators, Merck Sharp & Dohme LLC, and the study chair, Harpreet Wasan, MBBS, FRCP, from Imperial College London. Additionally, the revision number has been updated from v2.14.3 to v2.15.0.
    Difference
    53%
    Check dated 2025-04-16T14:25:13.000Z thumbnail image
  6. Check
    60 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.2 to version 2.14.3.
    Difference
    0.1%
    Check dated 2025-04-01T23:55:56.000Z thumbnail image
  7. Check
    96 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    1%
    Check dated 2025-02-24T22:50:49.000Z thumbnail image
  8. Check
    110 days ago
    Change Detected
    Summary
    The web page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.
    Difference
    1%
    Check dated 2025-02-10T15:54:33.000Z thumbnail image

Stay in the know with updates to Pembrolizumab for Cancer of Unknown Primary Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Cancer of Unknown Primary Clinical Trial page.